{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=61",
    "query": {
      "intervention": "Protein Control",
      "page": 61
    },
    "page_size": 10
  },
  "pagination": {
    "page": 61,
    "page_size": 10,
    "total_count": 3499,
    "total_pages": 350,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=62&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=60&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T17:45:02.826Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00027300",
      "title": "Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Natalizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 900,
      "start_date": "2001-11",
      "completion_date": "2005-01",
      "has_results": false,
      "last_update_posted_date": "2017-01-09",
      "last_synced_at": "2026-11-02T17:45:02.826Z",
      "location_count": 14,
      "location_summary": "Scottsdale, Arizona • Berkeley, California • Davis, California + 11 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00027300"
    },
    {
      "nct_id": "NCT00134394",
      "title": "Etanercept With Tacrolimus for Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Etanercept plus tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Medicine and Dentistry of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2005-02",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2008-08-07",
      "last_synced_at": "2026-11-02T17:45:02.826Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00134394"
    },
    {
      "nct_id": "NCT01934556",
      "title": "A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Ranibizumab 0.3 mg intravitreal injection",
          "type": "DRUG"
        },
        {
          "name": "Guided Laser Photocoagulation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Palmetto Retina Center, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 150,
      "start_date": "2013-11",
      "completion_date": "2018-04",
      "has_results": true,
      "last_update_posted_date": "2020-11-17",
      "last_synced_at": "2026-11-02T17:45:02.826Z",
      "location_count": 3,
      "location_summary": "Beverly Hills, California • West Columbia, South Carolina • Houston, Texas",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "West Columbia",
          "state": "South Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01934556"
    },
    {
      "nct_id": "NCT05011656",
      "title": "Blood Purification for the Treatment of Pathogen Associated Shock",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Septic Shock"
      ],
      "interventions": [
        {
          "name": "Seraph-100 + State of the Art Care",
          "type": "DEVICE"
        },
        {
          "name": "State of the Art Care",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "ExThera Medical Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2024-04-19",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-11-02T17:45:02.826Z",
      "location_count": 9,
      "location_summary": "Washington D.C., District of Columbia • Brunswick, Georgia • Ann Arbor, Michigan + 5 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Brunswick",
          "state": "Georgia"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Corvallis",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05011656"
    },
    {
      "nct_id": "NCT00279201",
      "title": "The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "Lispro Low Mix",
          "type": "DRUG"
        },
        {
          "name": "Lispro Mid Mix",
          "type": "DRUG"
        },
        {
          "name": "Lispro",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "30 Years to 79 Years"
      },
      "enrollment_count": 2091,
      "start_date": "2005-12",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2011-02-21",
      "last_synced_at": "2026-11-02T17:45:02.826Z",
      "location_count": 138,
      "location_summary": "Mobile, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 135 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00279201"
    },
    {
      "nct_id": "NCT02445651",
      "title": "Physiological Effects of Nutritional Support in Patients With Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Parkinson Disease",
        "Idiopathic Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Intravenous and Oral n-acetyl cysteine",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Control group",
          "type": "OTHER"
        },
        {
          "name": "Oral Supplements: Baicalin, Ganoderma, Omega 3 and Curcumin",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 51,
      "start_date": "2014-03",
      "completion_date": "2022-08-04",
      "has_results": true,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-11-02T17:45:02.826Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02445651"
    },
    {
      "nct_id": "NCT06439277",
      "title": "A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity",
        "Weight Gain"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 300,
      "start_date": "2024-06-03",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-11-02T17:45:02.826Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Sacramento, California • Wilmington, Delaware + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Ammon",
          "state": "Idaho"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06439277"
    },
    {
      "nct_id": "NCT00557401",
      "title": "An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastroesophageal Reflux"
      ],
      "interventions": [
        {
          "name": "XP19986 SR3, 20 mg QD",
          "type": "DRUG"
        },
        {
          "name": "XP19986 SR3, 40 mg QD",
          "type": "DRUG"
        },
        {
          "name": "XP19986 SR3, 60 mg QD",
          "type": "DRUG"
        },
        {
          "name": "XP19986 SR3, 30 mg BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "XenoPort, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 156,
      "start_date": "2007-11",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2021-02-21",
      "last_synced_at": "2026-11-02T17:45:02.826Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00557401"
    },
    {
      "nct_id": "NCT00605930",
      "title": "A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Progressive Supranuclear Palsy"
      ],
      "interventions": [
        {
          "name": "Pyruvate, creatine, niacinamide",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Louisville",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 20,
      "start_date": "2004-04",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2017-04-10",
      "last_synced_at": "2026-11-02T17:45:02.826Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00605930"
    },
    {
      "nct_id": "NCT00927394",
      "title": "Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Aliskiren",
          "type": "DRUG"
        },
        {
          "name": "Valsartan",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Aliskiren",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Valsartan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1143,
      "start_date": "2009-05",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2012-12-06",
      "last_synced_at": "2026-11-02T17:45:02.826Z",
      "location_count": 4,
      "location_summary": "Newark, Delaware • Kansas City, Missouri • Camden, New Jersey + 1 more",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Camden",
          "state": "New Jersey"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00927394"
    }
  ]
}